AVIR

Atea Pharmaceuticals' stock has experienced a price increase, trading at $5.43, a 52.1% increase from January 1st, 2026. The company reported its Q4 2025 financial results, missing EPS estimates but experiencing a positive stock reaction. Atea is expected to release its Q1 2026 results in May 2026. The company completed enrollment for its C-BEYOND Phase 3 clinical trial for HCV and expects topline results in mid-2026. Analysts have increased Atea Pharmaceuticals' price target. Atea announced the expansion of its antiviral pipeline into HEV. Atea's Board authorized the repurchase of up to $25 million of the company's common stock.